FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213337029> ?p ?o ?g. }

• W3213337029 endingPage "647.e2" @default.
• W3213337029 startingPage "645" @default.
• W3213337029 abstract "Immunocompromised patients, including those who received an organ transplant, were excluded from coronavirus disease 2019 (COVID-19) vaccine clinical trials.1Polack F.P. et al.N Engl J Med. 2020; 383: 2603-2615Crossref PubMed Scopus (8199) Google Scholar,2John B.V. et al.JAMA Intern Med. 2021; 181: 1306-1314Crossref PubMed Scopus (58) Google Scholar Transplant patients are at high risk of severe disease3Webb G.J. et al.Lancet Gastroenterol Hepatol. 2020; 5: 1008-1016Abstract Full Text Full Text PDF PubMed Scopus (165) Google Scholar but may not manifest adequate antispike antibody responses after COVID-19 vaccination, raising concern for persisting risk.4Boyarsky B.J. et al.JAMA. 2021; 325: 2204-2206Crossref PubMed Scopus (655) Google Scholar,5Boyarsky B.J. et al.JAMA. 2021; 325: 1784-1786Crossref PubMed Scopus (380) Google Scholar The objective of this study was to evaluate the effectiveness of COVID-19 vaccination for the prevention of COVID-19 and COVID-19–related death. Liver transplant recipients (aged > 18 years) in active care from December 15, 2020 to September 12, 2021 were identified from the Veterans Outcomes and Costs Associated with Liver Disease cohort using International Classification of Diseases codes.6John B.V. et al.Hepatology. 2021; 74: 879-891Crossref PubMed Scopus (28) Google Scholar,7John B.V. et al.Am J Gastroenterol. 2021; 116: 1913-1923Crossref PubMed Scopus (17) Google Scholar Patients were considered fully vaccinated 14 days after the second dose of either the Pfizer BNT162b2 mRNA or the Moderna 1273 mRNA. Patients who were unvaccinated, partially vaccinated (received only 1 dose of the vaccine or had fewer than 14 days of follow-up after the second dose) with an mRNA vaccine, or received the Janssen Ad26.SARS CoV2 vaccine were considered as control subjects. Outcomes evaluated included COVID-19 (documented by positive COVID-19 polymerase chain reaction), symptomatic COVID-19, and COVID-19–related death, assessed from the date of full vaccination (14 days after the second dose of an mRNA vaccine) for vaccinated patients and from the first availability of COVID-19 vaccines within the VA system (December 18, 2020) for unvaccinated patients. Propensity scores were derived through the logistic regression adjusted by the covariates of age group, sex, current smoking, kidney transplantation, comorbidities including chronic obstructive pulmonary disease and hypertension, primary immunosuppression, and antimetabolite therapy in patients who received vaccinations vs unvaccinated control subjects. Inverse propensity weights were calculated and used as weighted score into the unadjusted and adjusted hazard regression. Descriptive variables were compared using Wilcoxon and χ2 tests as appropriate. The hazard ratios of COVID-19 infection, symptomatic COVID-19, or COVID-19–related death associated with vaccination were estimated using Cox proportional hazard regression models, controlling for a priori determined variables known to be correlated with surviva,l and probability of being infected including age, body mass index, race, tobacco use, prior receipt of a kidney transplant, and time after transplantation.3Webb G.J. et al.Lancet Gastroenterol Hepatol. 2020; 5: 1008-1016Abstract Full Text Full Text PDF PubMed Scopus (165) Google Scholar Event-free cases and control subjects were censored at the end of the study period. Patients who received only 1 dose of an mRNA vaccine or the Ad26.SARS CoV2 vaccine were included as control subjects and censored on the date of receipt of the first dose. Vaccine efficacy was calculated as 1 minus risk ratio, where risk ratio is the ratio of risk after full vaccination among vaccinated to risk after the matched vaccine date among unvaccinated. Statistical significance was defined using 2-sided tests with α = 0.05. Statistical analysis was performed using SAS 4.9 (SAS Inc, Cary, NC). The study was approved by the institutional review boards at all participating VA medical centers. Of 1924 eligible liver transplant recipients, 1133 (58.9%) were fully vaccinated with 2 doses of an mRNA vaccine. Patients who were vaccinated were more likely to be men, white, have chronic obstructive pulmonary disease, be hypertensive, have received a kidney transplant, have received a calcineurin inhibitor plus antimetabolite, less likely to be active smokers, and were fewer years after transplantation (Supplementary Table 1). The outcomes of COVID-19 were observed in 24 of 1133 vaccinated and 43 of 791 control subjects, symptomatic COVID-19 in 14 vaccinated and 26 control subjects, and COVID-19–related death in 2 vaccinated and 11 control subjects. On multivariable analysis, full vaccination with a COVID-19 vaccine was associated with a significant reduction in COVID-19 (adjusted hazard ratio, 0.36; 95% confidence interval, 0.26–0.51; P < .0001), symptomatic COVID-19 (adjusted hazard ratio, 0.42; 95% confidence interval, 0.27–0.65; P < .0001), and COVID-19–related death (adjusted hazard ratio, 0.13; 95% confidence interval, 0.04–0.37; P = .0002) (Supplementary Table 2 and Figure 1). Of the 2 postvaccination COVID-19 deaths, the first was an 80-year-old man who was 9 years post-transplant on tacrolimus, with compensated graft cirrhosis, nonischemic cardiomyopathy, atrial fibrillation, and chronic kidney disease who developed COVID-19 18 days after the second dose of mRNA-1273 vaccine. This patient required mechanical ventilation, pressors, and dialysis and died from respiratory failure. The second patient was an 82-year-old man with coronary artery disease, diabetes mellitus, and chronic kidney disease who was 8 years post-transplant on single-agent tacrolimus and developed COVID-19 pneumonia 10 days after the second dose of the mRNA-1273 vaccine. He required noninvasive ventilation, refused intubation, and died of respiratory failure. Recent studies report concerning data that only 54% of solid organ transplant recipients, 43% on antimetabolite therapy and 46% of kidney transplant recipients, mount antispike antibodies after COVID-19 mRNA vaccine.4Boyarsky B.J. et al.JAMA. 2021; 325: 2204-2206Crossref PubMed Scopus (655) Google Scholar,5Boyarsky B.J. et al.JAMA. 2021; 325: 1784-1786Crossref PubMed Scopus (380) Google Scholar However, our data show that receipt of full vaccination with 2 doses of an mRNA vaccine was associated with a 64%% decrease in COVID-19 infection, 58% decrease in symptomatic COVID-19, and 87% decrease in COVID-19–related death in liver transplant recipients. Protection from the vaccination may be of lower magnitude than that observed in healthy individuals, yet it exceeds the level of protection predicted by antibody titers.4Boyarsky B.J. et al.JAMA. 2021; 325: 2204-2206Crossref PubMed Scopus (655) Google Scholar,5Boyarsky B.J. et al.JAMA. 2021; 325: 1784-1786Crossref PubMed Scopus (380) Google Scholar In addition to humoral immunity, adaptive T-cell–mediated responses may also confer vaccine protection and require further study. Similar observations have been reported with influenza in liver transplant recipients in whom, despite low antibody titers, vaccination has been associated with significant reduction in hospitalizations and death.8Kumar D. et al.Clin Infect Dis. 2018; 67: 1322-1329Crossref PubMed Scopus (117) Google Scholar Limitations of the present study include a retrospective design with potential for residual confounding, a male-predominant cohort, small numbers of outcomes, lack of measurement of antispike antibodies or T-cell response to COVID-19, and lack of systematic testing for severe acute respiratory syndrome coronavirus 2. Control subjects could have received the vaccine outside the VA, resulting in misclassification bias toward the null. Individuals in either group may have tested positive for COVID-19 outside the VA system, possibly more likely to have occurred in unvaccinated individuals and again biasing toward the null. The study was completed before the recommendation for a third dose of the mRNA BNT162b2 vaccine. Strengths of the present study include a large sample size for a geographically diverse, national transplant population. We were able to complete this study at a point where we had adequate numbers of unvaccinated control subjects. In summary, our findings show that full vaccination with 2 doses of a COVID-19 mRNA vaccine is associated with a decrease in COVID-19 infection and death in liver transplant recipients. Binu V. John, MD, MPH (Conceptualization: Lead; Funding acquisition: Lead; Investigation: Lead; Methodology: Equal; Supervision: Equal; Writing – original draft: Lead). Yangyang Deng, MS (Formal analysis: Lead; Investigation: Equal; Methodology: Equal; Software: Equal; Writing – review & editing: Supporting). Nidah S. Khakoo, MD (Data curation: Lead; Investigation: Equal; Validation: Equal; Writing – review & editing: Supporting). Tamar H. Taddei, MD (Funding acquisition: Supporting; Project administration: Equal; Resources: Equal; Writing – review & editing: Equal). David E. Kaplan, MD (Funding acquisition: Supporting; Methodology: Equal; Project administration: Equal; Writing – review & editing: Equal). Bassam Dahman, PhD (Data curation: Lead; Formal analysis: Lead; Methodology: Lead; Resources: Equal; Software: Lead; Supervision: Equal; Writing – review & editing: Equal). Supplementary Table 1Baseline Characteristics of Study ParticipantsVariablesVaccineControlP(n = 1133)(n = 791)Patient who received the first dose… Pfizer BNT162b2 mRNA vaccine539 (47.6)… Moderna 1273 mRNA vaccine596 (52.4)…Sex<.0001 Male1106 (97.6)736 (93.1) Female27 (2.4)55 (6.9)Median age, y (IQR)68.9 (7.9)68.6 (8.7).4629Age group.0184 <50 y30 (2.6)37 (4.7) 50–59.9 y110 (9.7)76 (9.6) 60–69.9 y516 (45.5)341 (43.1) 70–84.9 y477 (42.1)333 (42.1) >85 y0 (0.0)4 (0.5)White755 (66.6)479 (60.6).0062Median body mass index (IQR)30.2 (5.5)30.2 (4.8).3851Current smoker227 (20.0)180 (22.8).1505Chronic obstructive pulmonary disease319 (28.2)137 (17.3)<.0001Hypertension917 (80.9)562 (71.1)<.0001Kidney transplantation223 (19.7)117 (14.8).0057Tacrolimus917 (80.9)454 (57.4)<.0001Cyclosporine78 (6.9)47 (5.9).4092Calcineurin inhibitor–based primary immunosuppression1055 (93.1)568 (71.8)<.0001Mycophenolate610 (53.8)331 (41.8)<.0001Azathioprine86 (7.6)36 (4.5).0071Antimetabolites696 (61.4)367 (46.4)<.0001Median year from transplantation (IQR)5.6 (5.0)8.4 (7.5)<.0001Values are n (%) unless otherwise defined. IQR, interquartile range. Open table in a new tab Supplementary Table 2Inverse Probability of Treatment Weighting Multivariable Hazard Ratios for the Risk of COVID-19, Symptomatic COVID-19, and COVID-19–related Death, Comparing Liver Transplant Recipients Who Are Fully Vaccinated for COVID-19 With an mRNA Vaccine vs Control SubjectsVariableCOVID-19Symptomatic COVID-19COVID-19 related deathaHR (95% CI)PaHR (95% CI)PaHR (95% CI)PNumber of patients192419241924 Control791791791 Vaccine113311331133Number of events674013 Control432611 Vaccine24142Group ControlREFREFREF Vaccine0.36 (0.26–0.51)<.00010.42 (0.27–0.65)<.00010.13 (0.04–0.37).0002Age1.03 (0.97–1.04).72281.03 (0.98–1.03).80071.16 (1.05–1.28).0026Body mass index1.03 (1.01–1.06).00161.06 (1.03–1.09)<.00011.09 (1.04–1.14).0001Race NonwhiteREFREFREF White1.29 (0.93–1.78).13091.11 (0.74–1.67).61461.56 (0.63–3.90).3404Tobacco use Current nonsmokerREFREFREF Current Smoker1.20 (0.84–1.71).31541.48 (0.96–2.28).07802.54 (1.21–5.31).01353Kidney transplantation NoREFREFREF Yes1.11 (0.75–1.64).60851.03 (0.61–1.74).90791.32 (0.59–2.92).5010Year from transplantation0.94 (0.90–0.97).00070.96 (0.91–1.01).08470.94 (0.83–1.05).2778 Open table in a new tab Values are n (%) unless otherwise defined. IQR, interquartile range. COVID-19 Vaccination in Liver Transplant Recipients in View of Evidence-Based PolicymakingGastroenterologyVol. 163Issue 2PreviewWe read with great interest the study by John et al.1 The authors conducted a retrospective cohort analysis using a large database of veterans in the United States to capture liver transplant (LT) recipients, and found that full COVID-19 mRNA vaccine (2 doses) was associated with a lower incidence of COVID-19 infection, symptomatic COVID-19, and COVID-19–related death in LT recipients. Full-Text PDF" @default.
• W3213337029 created "2021-11-22" @default.
• W3213337029 creator A5007351094 @default.
• W3213337029 creator A5020110513 @default.
• W3213337029 creator A5043461307 @default.
• W3213337029 creator A5044402208 @default.
• W3213337029 creator A5050764284 @default.
• W3213337029 creator A5081723300 @default.
• W3213337029 date "2022-02-01" @default.
• W3213337029 modified "2023-09-29" @default.
• W3213337029 title "Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients" @default.
• W3213337029 cites W2796377403 @default.
• W3213337029 cites W3080747588 @default.
• W3213337029 cites W3111255098 @default.
• W3213337029 cites W3130961991 @default.
• W3213337029 cites W3137814380 @default.
• W3213337029 cites W3158948419 @default.
• W3213337029 cites W3161543778 @default.
• W3213337029 cites W3180415122 @default.
• W3213337029 doi "https://doi.org/10.1053/j.gastro.2021.11.001" @default.
• W3213337029 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8572555" @default.
• W3213337029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34758352" @default.
• W3213337029 hasPublicationYear "2022" @default.
• W3213337029 type Work @default.
• W3213337029 sameAs 3213337029 @default.
• W3213337029 citedByCount "22" @default.
• W3213337029 countsByYear W32133370292022 @default.
• W3213337029 countsByYear W32133370292023 @default.
• W3213337029 crossrefType "journal-article" @default.
• W3213337029 hasAuthorship W3213337029A5007351094 @default.
• W3213337029 hasAuthorship W3213337029A5020110513 @default.
• W3213337029 hasAuthorship W3213337029A5043461307 @default.
• W3213337029 hasAuthorship W3213337029A5044402208 @default.
• W3213337029 hasAuthorship W3213337029A5050764284 @default.
• W3213337029 hasAuthorship W3213337029A5081723300 @default.
• W3213337029 hasBestOaLocation W32133370291 @default.
• W3213337029 hasConcept C116675565 @default.
• W3213337029 hasConcept C126322002 @default.
• W3213337029 hasConcept C159047783 @default.
• W3213337029 hasConcept C203014093 @default.
• W3213337029 hasConcept C22070199 @default.
• W3213337029 hasConcept C2777648638 @default.
• W3213337029 hasConcept C2778137277 @default.
• W3213337029 hasConcept C2779134260 @default.
• W3213337029 hasConcept C3006700255 @default.
• W3213337029 hasConcept C3007834351 @default.
• W3213337029 hasConcept C3008058167 @default.
• W3213337029 hasConcept C524204448 @default.
• W3213337029 hasConcept C534529494 @default.
• W3213337029 hasConcept C71924100 @default.
• W3213337029 hasConceptScore W3213337029C116675565 @default.
• W3213337029 hasConceptScore W3213337029C126322002 @default.
• W3213337029 hasConceptScore W3213337029C159047783 @default.
• W3213337029 hasConceptScore W3213337029C203014093 @default.
• W3213337029 hasConceptScore W3213337029C22070199 @default.
• W3213337029 hasConceptScore W3213337029C2777648638 @default.
• W3213337029 hasConceptScore W3213337029C2778137277 @default.
• W3213337029 hasConceptScore W3213337029C2779134260 @default.
• W3213337029 hasConceptScore W3213337029C3006700255 @default.
• W3213337029 hasConceptScore W3213337029C3007834351 @default.
• W3213337029 hasConceptScore W3213337029C3008058167 @default.
• W3213337029 hasConceptScore W3213337029C524204448 @default.
• W3213337029 hasConceptScore W3213337029C534529494 @default.
• W3213337029 hasConceptScore W3213337029C71924100 @default.
• W3213337029 hasFunder F4320312140 @default.
• W3213337029 hasFunder F4320332161 @default.
• W3213337029 hasFunder F4320337351 @default.
• W3213337029 hasIssue "2" @default.
• W3213337029 hasLocation W32133370291 @default.
• W3213337029 hasLocation W32133370292 @default.
• W3213337029 hasLocation W32133370293 @default.
• W3213337029 hasOpenAccess W3213337029 @default.
• W3213337029 hasPrimaryLocation W32133370291 @default.
• W3213337029 hasRelatedWork W3005417802 @default.
• W3213337029 hasRelatedWork W3016529906 @default.
• W3213337029 hasRelatedWork W3020699490 @default.
• W3213337029 hasRelatedWork W3084498529 @default.
• W3213337029 hasRelatedWork W3119779361 @default.
• W3213337029 hasRelatedWork W3124487864 @default.
• W3213337029 hasRelatedWork W3134376730 @default.
• W3213337029 hasRelatedWork W3138412354 @default.
• W3213337029 hasRelatedWork W4206419631 @default.
• W3213337029 hasRelatedWork W3127156785 @default.
• W3213337029 hasVolume "162" @default.
• W3213337029 isParatext "false" @default.
• W3213337029 isRetracted "false" @default.
• W3213337029 magId "3213337029" @default.
• W3213337029 workType "article" @default.